EHMT2 and colon carcinoma: Verticillin A (13) demonstrated anticancer activity via chromatin remodeling, proving to be a potential candidate in overcoming colon carcinoma and pancreatic ductal adenocarcinoma (PDAC) cell resistance, mainly due to the selective inhibition of the histone methyltransferases (HMTases) SUV39H1, SUV39H2, G9a, GLP, NSD2 and MLL1 [83,84].